Celexa and Zoloft belong to the same class, sit on many of the same pharmacy shelves and are often described as interchangeable. The labels tell a more specific story: different approved conditions, a heart-rhythm warning that applies mainly to citalopram, and different rules for who needs a lower ceiling.
- Celexa (citalopram): FDA label covers major depressive disorder in adults.
- Zoloft (sertraline): label covers depression, OCD, panic disorder, PTSD, social anxiety disorder and PMDD.
- Biggest label difference: dose-dependent QT prolongation is a headline warning for citalopram; sertraline carries a precaution.
- Switching: always supervised; stopping an SSRI abruptly can cause discontinuation symptoms.
Someone is starting an SSRI and has heard of both names. Someone else has been on one for a year, and a new prescriber suggests the other. In both cases the question is the same: is this a lateral move, or does the label give a reason to prefer one? A direct comparison of the two prescribing documents answers part of that, and a large antidepressant analysis answers another part.
What each label approves
The current Celexa label on DailyMed describes Celexa as an SSRI “indicated for the treatment of major depressive disorder (MDD) in adults.” That is the full list. Many people take citalopram for anxiety, and clinicians do prescribe it that way, but those uses are off label. Our article on citalopram for anxiety and heart-rhythm risk covers that decision.
The Zoloft label lists six indications: major depressive disorder, obsessive-compulsive disorder, panic disorder, posttraumatic stress disorder, social anxiety disorder and premenstrual dysphoric disorder. It also states that safety and effectiveness in pediatric patients other than those with OCD have not been established.
Side by side
| Feature | Celexa (citalopram) | Zoloft (sertraline) |
|---|---|---|
| FDA-labeled uses | MDD in adults | MDD, OCD, panic disorder, PTSD, social anxiety disorder, PMDD |
| Label dose ceiling | 40 mg once daily; doses above 40 mg are not recommended because of QT prolongation | Up to 200 mg per day for adults and pediatric patients, stepped up gradually |
| Lower ceiling groups | 20 mg once daily for people over 60, hepatic impairment, CYP2C19 poor metabolizers and those taking CYP2C19 inhibitors | No age-based ceiling of this kind in the label sections reviewed |
| Heart-rhythm language | Warning: dose-dependent QTc prolongation, torsade de pointes and sudden death reported; avoid in congenital long QT syndrome, bradycardia, low potassium or magnesium, recent heart attack, uncompensated heart failure | Precaution: QTc prolongation and torsade cases reported, mostly with other risk factors; use caution if risk factors exist |
| Terminal half-life | About 35 hours | About 26 hours |
| Most common adverse reaction (at least 5% and twice placebo) | Ejaculation disorder, mainly delay | Nausea, diarrhea or loose stool, tremor, indigestion, decreased appetite, sweating, ejaculation failure, decreased libido |
Dose numbers in this table are label ceilings, not guidance for anyone’s own treatment. They are shown because they explain why one drug gets a conversation about ECGs and the other usually does not.
The QT question, put in proportion
The Celexa label says it causes dose-dependent QTc prolongation, an ECG finding associated with torsade de pointes, ventricular tachycardia and sudden death in postmarketing reports. It recommends against doses above 40 mg once daily and advises electrolyte monitoring for patients at risk of low potassium or magnesium. If symptoms such as dizziness, palpitations or fainting occur, the label directs prescribers to evaluate further, including cardiac monitoring, and to discontinue the drug if QTc measurements stay above 500 ms.
Sertraline’s label takes a milder position. It reports post-marketing cases of QTc prolongation and torsade de pointes, most confounded by other risk factors, and says use caution in patients with QTc risk factors. A thorough QT study found a positive relationship between sertraline concentration and QTc length, and the label does not set a QT-driven dose cap. In plain terms, neither drug is free of a rhythm question; citalopram has a harder ceiling and more explicit patient exclusions.
Fainting, a racing or irregular heartbeat, a family history of sudden cardiac death or long QT syndrome, low potassium (for example from water pills), and other QT-prolonging medicines such as some antiarrhythmics, antipsychotics and antibiotics all change the risk. Bring that list to the visit whichever SSRI is on the table.
Does one work better?
The largest comparison is the 2018 network meta-analysis in The Lancet covering 522 trials and 116,477 participants. It found every antidepressant more effective than placebo and described smaller differences between active drugs than between drugs and placebo. In head-to-head studies, escitalopram was among the drugs more effective than others; citalopram and sertraline were both in the group more tolerable than others, judged by dropouts. The authors rated the certainty of evidence as moderate to very low. Practical reading: on average the two perform similarly, and the average does not predict how one person will respond.
That is why a switch is usually about tolerability, the label, or a coexisting condition, not about a ranking. If the main target is OCD, panic disorder or PTSD, sertraline is the one with that wording in its approved indications. If heart rhythm is the concern, the citalopram label is the more restrictive of the two. If sexual side effects are the problem, both labels list them, and the Zoloft label states that prescribers should ask about sexual function before and during treatment.
Common reasons people end up comparing them
- Early nausea or loose stools on sertraline. Listed among its most common reactions. Whether this settles or justifies a change is a prescriber call.
- Ejaculation delay or low libido on either drug. Both labels discuss sexual dysfunction. Do not stop without advice; discuss alternatives.
- An ECG or electrolyte result. A borderline QTc or low potassium may point a prescriber toward or away from citalopram.
- A new interacting medicine. Citalopram’s label sets a lower maximum when taken with CYP2C19 inhibitors; sertraline’s label has its own interaction list, including a contraindication with pimozide.
- Age. People over 60 face a lower ceiling on citalopram, based on a higher drug exposure the label reports in older adults (AUC about 23% to 30% higher in the studies it describes).
Switching: why it is not a one-step swap
Both labels warn that adverse reactions can follow abrupt discontinuation of serotonergic antidepressants. The Zoloft label says to reduce the dosage gradually rather than stopping abruptly whenever possible, and lists symptoms such as nausea, sweating, dysphoric mood, irritability, agitation and dizziness. Starting a second SSRI while the first is still in your system also raises the chance of serotonin syndrome, a risk both labels cover. The practical rule is simple: do not combine, double up or stop on your own. A prescriber chooses the schedule, and the same pharmacist can check both bottles.
If you are trying to tell a discontinuation reaction from a return of depression after a change, see changing or stopping antidepressants safely. For what to expect from the drug you are currently taking, citalopram side effects lists early changes and serious warnings.
Interactions that differ between the two
Both labels contraindicate MAOIs, including linezolid and intravenous methylene blue, and pimozide, because of serotonin syndrome and QT concerns. Beyond that, the interaction sections diverge. The Celexa label sets a lower maximum when the drug is used with a CYP2C19 inhibitor such as cimetidine, because higher citalopram levels are expected. The Zoloft label instead advises monitoring when it is combined with protein-bound drugs such as warfarin and reducing the dosage of drugs metabolized by CYP2D6. The Zoloft oral solution has an extra contraindication with disulfiram because the solution contains alcohol, which applies to the liquid and not the tablets.
The practical lesson is that the interaction check has to be redone after a switch, not carried over from the old drug. A pharmacist reviewing the list can do this in minutes, and it is the cheapest safety step in the whole process.
Timing: why a switch is a plan, not a day
Both labels report that steady-state levels are reached in about a week of once-daily dosing, with terminal half-lives of about 35 hours for citalopram and about 26 hours for sertraline. Drug levels therefore fall and rise over days, not hours. This is part of why prescribers choose between stopping one drug and starting the next, tapering one while starting the other, or a staged overlap, and why symptoms that look like a new side effect in the first week may reflect a mix of both drugs. Which route is used depends on the doses, the reason for the switch and your history, and it is a clinician’s call. If you are watching for symptoms, our citalopram timeline guide sets realistic expectations for the first weeks.
Warnings that apply to both
Both prescribing documents carry the antidepressant boxed warning about increased suicidal thoughts and behaviors in children, adolescents and young adults. Anyone starting or changing an SSRI, and their family, should know to report new agitation, worsening mood or suicidal thoughts right away. In the U.S., the 988 Suicide & Crisis Lifeline is available by call or text at 988. Bleeding risk with aspirin, NSAIDs and anticoagulants and low sodium (hyponatremia) are also in both labels and are worth mentioning to the pharmacist.
Questions for the visit
- Which label-approved use applies to me, and are we using the drug off label?
- Do I have any QT risk factor (ECG, potassium, other medicines, family history)?
- What specific problem would a switch fix, and what could it make worse?
- How will the first drug be tapered and how will we watch for symptoms in the meantime?
- Which warning signs mean I should call the same day?
Sources
- DailyMed: Celexa (citalopram) label
- DailyMed: Zoloft (sertraline) label
- Cipriani et al., Lancet 2018: 21 antidepressants network meta-analysis (PubMed)
Evidence checked October 30, 2026. General information only; do not start, stop or change an antidepressant without your prescriber.